Kura Oncology reports preliminary cash balance of ~$438M as of Dec 31, 2022

Kura Oncology, Inc.

Preliminary unaudited cash, cash equivalents and short-term investments were approximately $438 million.
Cash balance is subject to completion of financial closing and audit; actual results may differ.
Company updated its corporate presentation materials (Exhibit 99.1), but substantive details not provided in filing.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.